A Study of Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer Who Have Received Prior Anti-HER2 And Chemotherapy-based Treatment

NCT01702571 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

2185

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Trastuzumab Emtansine

Sponsor

Hoffmann-La Roche